Last 42.00 GBp
Change Today 0.00 / 0.00%
Volume 279.5K
As of 11:35 AM 08/23/13 All times are local (Market data is delayed by at least 15 minutes).

proteome sciences plc (PRM) Snapshot

Open
42.25 GBp
Previous Close
42.00 GBp
Day High
42.25 GBp
Day Low
42.00 GBp
52 Week High
03/25/13 - 74.00 GBp
52 Week Low
08/29/12 - 29.75 GBp
Market Cap
82.4M
Average Volume 10 Days
380.2K
EPS TTM
-0.02 GBp
Shares Outstanding
196.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
PRM:LN Advanced Stock Chart

Related News

No related news articles were found.

proteome sciences plc (PRM) Related News

No Related News Found

proteome sciences plc (PRM) Key Developments

Proteome Sciences plc Announces Technology Agreement with Thermo Fisher Scientific to Develop Advanced Methods to Profile Changes in Key Cancer Pathways

Proteome Sciences announced a technology agreement with Thermo Fisher Scientific, valued at $2.1 million by Proteome Sciences, to develop advanced methods to profile changes in key cancer pathways. Proteome Sciences will provide Thermo Fisher with access to its patents covering a three-stage mass spectrometry (MS3) fragmentation methodology to deliver significantly improved analysis and accuracy. Proteome Sciences will receive cash and Thermo Fisher will provide a no-cost lease for mass spectrometry equipment for Proteome Sciences to develop the pathway assays. In addition Proteome Sciences will continue to develop advanced 20 and 30-plex Tandem Mass Tags (TMT®) for Thermo Fisher for the next additions to the TMT® range of tags. The new MS3 TMT® (three-stage MS Tandem Mass Tag) mass spectrometry technique is a breakthrough mass spectrometry based workflow, enabling mass spectrometers to determine relative quantitation of proteins in multiple samples simultaneously and with improved accuracy. Proteome Sciences will leverage the combined power of TMT® and Orbitrap® technology to develop an expanded range of mass spectrometry assays for the pharmaceutical industry. Through its SysQuant® workflows, Proteome will profile the low-level changes in activity of key cancer signalling pathways to facilitate optimal drug selection across a range of solid tumours. This will enable clinicians to provide real-time patient management and the ability, for the first time, to deliver truly personalised medicine.

Proteome Sciences plc Reports Preliminary Unaudited Consolidated Earnings Results for the Year Ended December 31, 2012; Provides Earnings Guidance for the Full Year 2013

Proteome Sciences plc reported preliminary unaudited consolidated earnings results for the year ended December 31, 2012. For the period, the company’s revenue was £1,152,967 against £1,021,167 a year ago. Loss before taxation was £5,195,487 against £4,510,255 a year ago. Loss for the period from continuing operations was £4,253,594 against £3,957,341 a year ago. Loss attributed to shareholders of the company was £4,253,594 or 2.21 pence basic and diluted per share against £3,957,341 or 2.06 pence basic and diluted per share a year ago. Net cash outflow from operating activities was £3,353,367 against £5,166,290 a year ago. Purchases of property, plant and equipment was £14,603 against £206,235 a year ago. The company expects a strong performance during the year 2013 from licenses, products and services as the company continue to raise corporate and research profile and these should be reflected in a sharp increase in the level of revenue in 2013 with the goal to be cash generative and sustainably profitable.

Proteome Sciences plc Auditor Raises 'Going Concern' Doubt

Proteome Sciences plc filed its Annual on May 30, 2013 for the period ending Dec 31, 2012. In this report its auditor, Deloitte & Touche LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRM:LN 42.00 GBp 0.00

PRM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRM.

Industry Analysis

PRM

Industry Average

Valuation PRM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 67.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 68.4x
 | 

Post a JobJobs


    We are currently experiencing technical difficulties. Please try again later.
Simply Hired

Sponsored Links


otc, otcbb, pinksheet, PRM, ob Pro Minerals Inc


Pro Minerals Inc Stock

Pro Minerals Inc. engages in the acquisition, exploration, and development of mineral properties in Ontario and Quebec, Canada. It primarily explores for gold, silver, copper, and zinc. The company principally holds interests in the Discovery Lake VMS project that consists of 36 mineral claims totaling an area of approximately 5,059 hectares and is located in the Petawanga Lake (Fort Hope) area of the Thunder Bay Mining District in northern Ontario; and the Shining Tree gold project, which consists of 1 mineral claim covering an area of approximately 72 hectares and is situated within the Abitibi Greenstone belt in Churchill Township, north-eastern Ontario. Pro Minerals Inc. was founded in 2006 and is headquartered in Vancouver, Canada.
No related news found for this Pro Minerals Inc.


All quotes are delayed. All information is provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Quote Stock nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing Quote Stock, you agree to our disclaimer.
@2013 www.quote-stocks.com is a part of The Stock Space financial network – (646) 402-6200. ContactUs Disclamier Privacy Policy